Abstract:Abstract In patients with end-stage renal disease (ESRD) undergoing dialysis, hypertension is common but often inadequately controlled. The prevalence of hypertension varies widely among studies because of differences in the definition of hypertension and the methods of used to measure blood pressure (BP), i.e., peri-dialysis or ambulatory BP monitoring (ABPM). Recently, ABPM has become the gold standard for diagnosing hypertension in dialysis patients. Home BP monitoring can also be a good alternative to ABPM, emphasizing BP measurement outside the hemodialysis (HD) unit. One thing for sure is pre- and post-dialysis BP measurements should not be used alone to diagnose and manage hypertension in dialysis patients. The exact target of BP and the relationship between BP and all-cause mortality or cause-specific mortality are unclear in this population. Many observational studies with HD cohorts have almost universally reported a U-shaped or even an L-shaped association between BP and all-cause mortality, but most of these data are based on the BP measured in HD units. Some data with ABPM have shown a linear association between BP and mortality even in HD patients, similar to the general population. Supporting this, the results of meta-analysis have shown a clear benefit of BP reduction in HD patients. Therefore, further research is needed to determine the optimal target BP in the dialysis population, and for now, an individualized approach is appropriate, with particular emphasis on avoiding excessively low BP. Maintaining euvolemia is of paramount importance for BP control in dialysis patients. Patient heterogeneity and the lack of comparative evidence preclude the recommendation of one class of medication over another for all patients. Recently, however, β-blockers could be considered as a first-line therapy in dialysis patients, as they can reduce sympathetic overactivity and left ventricular hypertrophy, which contribute to the high incidence of arrhythmias and sudden cardiac death. Several studies with mineralocorticoid receptor antagonists have also reported promising results in reducing mortality in dialysis patients. However, safety issues such as hyperkalemia or hypotension should be further evaluated before their use.

Beta-blockers Increase Cardiovascular Mortality in Hemodialysis Patients with Orthostatic Hypotension

β-blocker dialyzability and the risk of mortality and cardiovascular events in patients undergoing hemodialysis

Comparison of β-Blocker Agents and Mortality in Maintenance Hemodialysis Patients: An International Cohort Study

β-Blocker dialyzability and mortality in older patients receiving hemodialysis

Long‐term Predialysis Blood Pressure Variability and Outcomes in Hemodialysis Patients

Long-Term Predialysis Systolic Blood Pressure Variability and Intradialytic Cardiac Hemodynamics in Hemodialysis Patients

Association between beta-blocker utilization and heart failure mortality in the peritoneal dialysis population: a cohort study

Effects of beta-blocker use on volume status in hemodialysis patients.

Interdialytic Blood Pressure and Risk of Cardiovascular Events and Death in Hemodialysis Patients

Beta blockers are associated with lower all-cause mortality among HFpEF patients

Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease

Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients

The association of sex differences in ambulatory blood pressure with cardiovascular events and mortality in dialysis patients

Blood Pressure Before Initiation of Maintenance Dialysis and Subsequent Mortality

Associations Between Home Blood Pressure and Mortality in Peritoneal Dialysis

The Associations of Blood Pressure Parameters with All-Cause and Cardiovascular Mortality in Peritoneal Dialysis Patients: a Cohort Study in China.

Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study

The Epidemiology of Systolic Blood Pressure and Death Risk in Hemodialysis Patients

Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

Diagnosis and treatment of hypertension in dialysis patients: a systematic review

Intra-dialytic Blood Pressure Variability is a Greater Predictor of Cardiovascular Events in Hemodialysis Patients